Oral Vaccination Against Enteric Bacterial Infections: an Overview

Overview

Journal Infection

Date 1985 Jan 1

PMID 3902655

Authors

R Germanier

Affiliations

Soon will be listed here.

Abstract

The present situation and the future prospects for the use of oral vaccines against the major enteric diseases typhoid fever, shigellosis and cholera are discussed in this paper. No significant protection could be demonstrated for oral inactivated whole-cell vaccines. In contrast, an oral live vaccine based on the attenuated Salmonella typhi strain Ty 21a was highly efficacious in volunteer challenge studies and in a controlled field trial. Two attenuated strains are presently being tested in volunteer studies as candidate vaccines against shigellosis; one uses S. typhi Ty 21a and the other Escherichia coli K-12 as the carrier for shigella antigens. Experimental challenge studies in volunteers showed that recovery from clinical cholera confers solid and long-lasting protection. The goal of present research is to develop a vaccine that mimics the events of clinical cholera without causing disease.

References

Chuttani C, Prakash K, Vergese A, Sharma U, Singha P, RAY B . Effectiveness of oral killed typhoid vaccine. Bull World Health Organ. 1971; 45(4):445-50. PMC: 2427945. View

Germanier R, Fuer E . Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975; 131(5):553-8. DOI: 10.1093/infdis/131.5.553. View

Chuttani C, Prakash K, Gupta P, Grover V, Kumar A . Controlled field trial of a high-dose oral killed typhoid vaccine in India. Bull World Health Organ. 1977; 55(5):643-4. PMC: 2366700. View

Levine M, Black R, Clements M, Young C, Lanata C, Sears S . Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate. Dev Biol Stand. 1983; 53:59-65. View

Levine M, DuPont H, Hornick R, Snyder M, Woodward W, Gilman R . Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. J Infect Dis. 1976; 133(4):424-9. DOI: 10.1093/infdis/133.4.424. View

Levine M, Black R, Clements M, Cisneros L, Nalin D, Young C . Duration of infection-derived immunity to cholera. J Infect Dis. 1981; 143(6):818-20. DOI: 10.1093/infdis/143.6.818. View

Formal S, Baron L, Kopecko D, WASHINGTON O, Powell C, Life C . Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun. 1981; 34(3):746-50. PMC: 350934. DOI: 10.1128/iai.34.3.746-750.1981. View

Gilman R, Hornick R, Woodard W, DuPont H, Snyder M, Levine M . Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis. 1977; 136(6):717-23. DOI: 10.1093/infdis/136.6.717. View

Cash R, Music S, Libonati J, Craig J, Pierce N, Hornick R . Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis. 1974; 130(4):325-33. DOI: 10.1093/infdis/130.4.325. View

10.

Wahdan M, SERIE C, Cerisier Y, Sallam S, Germanier R . A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982; 145(3):292-5. DOI: 10.1093/infdis/145.3.292. View

11.

DuPont H, Hornick R, Snyder M, Dawkins A, Heiner G, WOODWARD T . Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull World Health Organ. 1971; 44(5):667-72. PMC: 2427859. View

12.

Sansonetti P, Hale T, DAMMIN G, Kapfer C, Collins Jr H, Formal S . Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun. 1983; 39(3):1392-402. PMC: 348110. DOI: 10.1128/iai.39.3.1392-1402.1983. View